FDA OKs Roche’s Tecentriq for Some NSCLC Patients

FDA OKs Roche’s Tecentriq for Some NSCLC Patients

Roche’s blockbuster monoclonal antibody Tecentriq (atezolizumab) got another approval from the FDA, this time for certain nonsmall-cell lung cancer (NSCLC) patients.

 The agency greenlighted the cancer immunotherapy for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1 percent of tumor cells, as determined by an FDA-approved test.

 A phase 3 trial showed that Tecentriq treatment after surgery and platinum-based chemotherapy lowered the disease recurrence or mortality risk by 34 percent in PD-L1-positive stage II-IIIA NSCLC patients vs. best supportive care, Roche said.

 October 20, 2021

 https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company